Brenipatide, a Lilly incretin-class compound reported to be a dual GIP/GLP-1 agonist, was never positioned around obesity the way tirzepatide was. This desk’s earlier coverage examined the company’s decision to lead with neuropsychiatric indications instead, addiction and mood disorders specifically, a real departure from how this drug class typically enters the market. That bet has since scaled considerably. Lilly now has brenipatide in six psychiatric and addiction indications at once, in Phase 3 for major depression and alcohol use disorder and in Phase 2 for bipolar disorder, smoking, opioid use disorder, and schizophrenia, a breadth of concurrent neuropsychiatric development this desk has not seen matched by any other compound covered this year.
The current program, mapped out
RENEW-MDD-1, registered under NCT07412756, is a Phase 3 trial testing brenipatide as an adjunct to standard antidepressant care, evaluating whether it delays the return of depressive symptoms in adults with major depressive disorder, a relapse-prevention design rather than an acute-response trial. It is one of two Phase 3 depression trials Lilly has registered. Alcohol use disorder is the second Phase 3 indication, run across two trials of its own, RENEW-ALC-1 and RENEW-ALC-2, each enrolling roughly 1,100 participants, the largest of brenipatide’s current studies by enrollment. Those four trials, two in depression and two in alcohol use disorder, are the full extent of brenipatide’s Phase 3 development. Everything else sits at Phase 2: RENEW-Bipolar-1 in bipolar disorder and RENEW-Smk-1 in smoking-cessation relapse prevention, both following the same adjunctive relapse-prevention logic as the depression trial rather than testing acute treatment directly, alongside RENEW-Op-1 in opioid use disorder, enrolling 465 participants dosed alongside buprenorphine with or without naloxone, and RENEW-Scz-1 in schizophrenia. Earlier-stage work continues in asthma, obesity, and cardiovascular and liver disease, indications closer to the drug class’s traditional metabolic territory.
Why the relapse-prevention framing matters
Both the MDD and smoking cessation programs share a specific design logic: brenipatide is not being tested as a replacement for existing treatment, but as an addition intended to keep symptoms from returning once initial treatment has already worked. That is a materially different commercial and clinical proposition than a standalone antidepressant or cessation aid. It positions brenipatide as infrastructure sitting underneath existing standard of care rather than competing with it directly, a strategy that, if the data holds up, could make brenipatide easier to add to an existing treatment regimen than a drug asking prescribers to switch a patient off something already working.
The mechanistic rationale, and its limits
Lilly’s rationale for testing a metabolic drug class across this range of psychiatric and addiction indications rests substantially on preclinical work with tirzepatide, the related dual agonist, showing attenuation of alcohol-induced dopamine signaling in rodent models. That is a real, publishable mechanistic hypothesis connecting GIP/GLP-1 receptor activity to reward and craving circuitry generally, which would explain interest across multiple substance-use and mood indications at once. It is also, as of this year, entirely preclinical and cross-compound reasoning rather than confirmed human evidence specific to brenipatide itself. No Phase 2 or Phase 3 results for brenipatide, in any indication, have been publicly reported.
Why the breadth itself is the notable signal
A single compound in six neuropsychiatric indications at once, four of its trials already at Phase 3, before any of them has reported results, is an unusually capital-intensive and unusually confident bet even by large pharma standards. It suggests Lilly’s own internal read of brenipatide’s mechanism is broad enough to justify parallel, expensive investment across mood, multiple substance-use disorders, and psychosis all at once, rather than the more typical approach of proving the mechanism in one indication before expanding. That is either a sign of unusually strong internal confidence in the underlying biology, or a hedge against the real possibility that not every indication will pan out, run enough parallel bets and something is likely to read out positively even if others don’t.
The caveats
Every efficacy claim about brenipatide beyond its metabolic mechanism remains unproven in humans as of this writing; the addiction and mood rationale rests on preclinical, cross-compound evidence, not brenipatide-specific trial data. No brenipatide trial has reported results, and the Phase 3 studies remain in enrollment, so any regulatory submission is years away and depends entirely on data this desk has not yet seen. Running four Phase 3 trials at once is not itself evidence any of them will succeed; large pharmaceutical companies routinely run parallel bets that don’t all pay off.
The frame
This desk’s original brenipatide coverage flagged an unusual strategic choice: leading a metabolic drug class with psychiatric and addiction indications rather than obesity. That choice has since scaled into one of the broadest simultaneous neuropsychiatric development programs this desk has tracked for a single compound, six psychiatric and addiction indications running at once, four of its trials already at Phase 3, entirely ahead of any brenipatide-specific human efficacy data becoming public. Whether that breadth reflects real confidence in a shared underlying mechanism or a portfolio hedge across a mechanism the company isn’t yet certain will work in any single indication is a question none of the current public data can answer. The next real test is not whether Lilly keeps expanding brenipatide’s reach, it clearly is, but whether any of those four Phase 3 trials reads out.